As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Praxis Precision Medicines Inc. The largest reported stake is Janus Henderson Group Plc's, at 12.3%. 26 filings are on record since July 22, 2025 (Schedule 13G/A, November 14, 2025).
Who owns Praxis Precision Medicines, Inc.?
Sell to companies like Praxis Precision Medicines Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 2,561,602 · Shared voting: 0 · Sole dispositive: 2,565,828 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Orbis Investment Management Ltd · Sole voting: 1,526,680 · Shared voting: 0 · Sole dispositive: 1,526,680 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Point72 Biotech Private Investments, LLC · Percent: 0.2% · SCHEDULE 13G/A
- · Holder: Orbis Investment Management Ltd · Percent: 8.9% · SCHEDULE 13G/A
- · Holder: Baker Bros. Advisors LP · Percent: 6.3% · SCHEDULE 13G
Praxis Precision Medicines Inc. has 26 Schedule 13D or 13G filings on record since 2025-07-22. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 12.3% | 2,763,859 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Fmr LLC | 9.2% | 2,565,828 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Perceptive Advisors LLC | 7.2% | 1,995,986 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Baker Bros. Advisors LP | 6.3% | 1,753,198 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Orbis Investment Management Ltd | 5.5% | 1,526,680 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vanguard Capital Management | 5.09% | 1,419,323 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| T. Rowe Price Associates, Inc. | 4.8% | 1,003,545 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Soleus Capital Master Fund, L.P. | 4.6% | 966,740 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 |
| Cormorant Asset Management, LP | 4% | 1,000,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Adage Capital Management, L.P. | 3.83% | 965,313 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| 2.9% | 617,980 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 | |
| Point72 Biotech Private Investments, LLC | 0.2% | 65,933 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Praxis Precision Medicines Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Praxis Precision Medicines Inc. and the records around it.
Praxis Precision Medicines Inc. elsewhere on the record
Companies that share a holder
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- ORBIS INVESTMENT MANAGEMENT LTD also filed stake reports on 23 other companies: RXO, Inc. (Nov 2026), National CineMedia, Inc. (Sep 2026), BBB FOODS INC (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Praxis Precision Medicines Inc.
Get an email when Praxis Precision Medicines Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Praxis Precision Medicines Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Praxis Precision Medicines Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Praxis Precision Medicines Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 2,561,602 | 0 | 2,565,828 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 2,565,828 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Orbis Investment Management Ltd | 1,526,680 | 0 | 1,526,680 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Allan Gray Australia Pty Ltd | 3,108 | 0 | 3,108 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Praxis Precision Medicines Inc. by CUSIP 74006W207 and gives its principal executive office as 99 HIGH STREET, 30TH FLOOR, BOSTON, MA 02110 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-22 | Perceptive Advisors LLC | 6.69% | SCHEDULE 13G |
| 2025-08-05 | Soleus Capital Master Fund, L.P. | 4.6% | SCHEDULE 13G/A |
| 2025-08-12 | Adage Capital Management, L.P. | 9.69% | SCHEDULE 13G/A |
| 2025-08-14 | Steven A. Cohen | 7.3% | SCHEDULE 13G/A |
| 2025-08-14 | Cormorant Asset Management, LP | 7.72% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 12.4% | SCHEDULE 13G/A |
| 2025-09-02 | Adage Capital Management, L.P. | 11.28% | SCHEDULE 13G/A |
| 2025-11-03 | Adage Capital Management, L.P. | 5.29% | SCHEDULE 13G/A |
| 2025-11-07 | Morgan Stanley | 2.9% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 4.8% | SCHEDULE 13G/A |
| 2025-11-14 | Steven A. Cohen | 9.6% | SCHEDULE 13G/A |
| 2025-11-14 | Cormorant Asset Management, LP | 4% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 12.3% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 5.4% | SCHEDULE 13G |
| 2026-02-12 | Adage Capital Management, L.P. | 3.83% | SCHEDULE 13G/A |
| 2026-02-17 | Steven A. Cohen | 6.1% | SCHEDULE 13G/A |
| 2026-02-17 | Orbis Investment Management Ltd | 5% | SCHEDULE 13G |
| 2026-02-17 | Perceptive Advisors LLC | 7.2% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 7.7% | SCHEDULE 13G/A |
| 2026-05-15 | Point72 Biotech Private Investments, LLC | 0.2% | SCHEDULE 13G/A |
| 2026-05-15 | Orbis Investment Management Ltd | 8.9% | SCHEDULE 13G/A |
| 2026-05-15 | Baker Bros. Advisors LP | 6.3% | SCHEDULE 13G |
| 2026-08-14 | Orbis Investment Management Ltd | 5.5% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 9.2% | SCHEDULE 13G/A |
Questions about who owns Praxis Precision Medicines Inc.
Who owns Praxis Precision Medicines Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Praxis Precision Medicines Inc.: Janus Henderson Group Plc (12.3%, Schedule 13G/A, filed 2025-11-14), Fmr LLC (9.2%, Schedule 13G/A, filed 2026-11-05), Perceptive Advisors LLC (7.2%, Schedule 13G/A, filed 2026-02-17), Baker Bros. Advisors LP (6.3%, Schedule 13G, filed 2026-05-15) and Orbis Investment Management Ltd (5.5%, Schedule 13G/A, filed 2026-08-14); 1 more is listed above.
Who are the largest shareholders of Praxis Precision Medicines Inc.?
By the share each holder's latest filing reports, the largest holders of Praxis Precision Medicines Inc. on this page are Janus Henderson Group Plc (12.3%), Fmr LLC (9.2%) and Perceptive Advisors LLC (7.2%).
When did Janus Henderson Group Plc buy into Praxis Precision Medicines Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G/A, filed 2025-08-14, reporting 12.4%; its latest, Schedule 13G/A filed 2025-11-14, reports 12.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 26 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Praxis Precision Medicines Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.